Stempoint Capital LP Purchases 228,442 Shares of SAB Biotherapeutics, Inc. $SABS

Posted by Brian Himes on Jul 30th, 2026

Stempoint Capital LP increased its position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS – Free Report) by 155.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 375,000 shares of the company’s stock after purchasing an additional 228,442 shares during the period. Stempoint Capital LP owned approximately 0.74% of SAB Biotherapeutics worth $1,436,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. purchased a new stake in SAB Biotherapeutics in the 1st quarter worth about $29,000. ADAR1 Capital Management LLC purchased a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $30,000. Dimensional Fund Advisors LP purchased a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $32,000. State of Wyoming bought a new position in shares of SAB Biotherapeutics during the fourth quarter valued at approximately $34,000. Finally, Virtu Financial LLC bought a new position in shares of SAB Biotherapeutics during the third quarter valued at approximately $40,000. 7.82% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on SABS shares. Barclays initiated coverage on SAB Biotherapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating and a $13.00 price target for the company. Leerink Partners upped their price objective on SAB Biotherapeutics from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, June 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Citigroup began coverage on SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Wednesday, July 8th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, SAB Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $12.00.

Read Our Latest Report on SABS

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock opened at $3.48 on Thursday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The company has a market capitalization of $266.08 million, a PE ratio of -1.65 and a beta of 0.52. The company has a 50 day moving average price of $3.68 and a 200-day moving average price of $3.84. SAB Biotherapeutics, Inc. has a fifty-two week low of $1.85 and a fifty-two week high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). As a group, equities analysts forecast that SAB Biotherapeutics, Inc. will post -1.19 earnings per share for the current year.

SAB Biotherapeutics Profile

(Free Report)

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.